A Skeptical Take on Current Alzheimer’s Therapy: FDA’s Temple Says Problem Is Drugs, Not Endpoints

Everyone agrees that Alzheimer’s Disease is one of the most important areas of unmet need in medicine. No one doubts that a therapy that slows or halts the progression of the disease would have profound positive benefits for society.

Where some people disagree is on exactly what FDA should be doing about it. Within industry, Alzheimer’s is often cited...